Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon (Q26830435)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Satoru Hagiwara

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Naoshi Nishida

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

1 reference

1 October 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

World Journal of Hepatology

27 February 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

2427-2431

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

23

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

27 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Immunology of hepatitis B virus and hepatitis C virus infection

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Kinetics of the immune response during HBV and HCV infection.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Reduction of HBV replication prolongs the early immunological response to IFNα therapy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

31 May 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.4254%2FWJH.V7.I23.2427

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4606198

Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/26483864

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/26483864

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4254/WJH.V7.I23.2427

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26483864%20AND%20SRC:MED&resulttype=core&format=json